EU Pharmaceutical Industry: Counterfeit pharmaceutical and healthcare products pose a threat to European consumers - by Elena Pavlovska

 With a global pandemic still wreaking havoc across the globe and while the world awaits a vaccine for COVID-19, much of the public’s attention is focused on the pharmaceutical industry.

New Europe’s Elena Pavlovska spoke with the European Union Intellectual Property Office (EUIPO) about the health and safety risks that counterfeit pharmaceutical and healthcare products pose to consumers, as well as the main objective of the counterfeiters.

The interview follows a new study released by EUIPO and the Organisation for Economic Cooperation and Development. The research has found that counterfeit medicines can be harmful to a patient’s health, because they do not comply with intellectual property law.

The study is part of the #YourHealthIsPriceless campaign, which aims to raise awareness of the harms that counterfeit pharmaceutical and healthcare products can cause.

Read more at: 
Counterfeit pharmaceutical and healthcare products pose a threat to European consumers | New Europe